Publication Date:
1984-06-01
Description:
The effectiveness of adriamycin in the treatment of ovarian cancer and other human tumors has been limited by the development of drug resistance. Verapamil, a calcium channel blocking agent, completely reversed adriamycin resistance in human ovarian cancer cells with moderate (three- to sixfold) degrees of resistance and partially reversed resistance in highly (150-fold) resistant cells. The potentiating effect of verapamil was due to inhibition of adriamycin efflux in the resistant cells. These results have led to a clinical trial of adriamycin and verapamil in refractory ovarian cancer patients.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Rogan, A M -- Hamilton, T C -- Young, R C -- Klecker, R W Jr -- Ozols, R F -- New York, N.Y. -- Science. 1984 Jun 1;224(4652):994-6.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/6372095" target="_blank"〉PubMed〈/a〉
Keywords:
Cell Line
;
Clinical Trials as Topic
;
Dose-Response Relationship, Drug
;
Doxorubicin/*therapeutic use
;
Drug Resistance
;
Female
;
Humans
;
Ovarian Neoplasms/*drug therapy
;
Verapamil/*therapeutic use
Print ISSN:
0036-8075
Electronic ISSN:
1095-9203
Topics:
Biology
,
Chemistry and Pharmacology
,
Computer Science
,
Medicine
,
Natural Sciences in General
,
Physics
Permalink